Among patients with untreated CLL and coexisting conditions, venetoclax-obinutuzumab was associated with longer progression-free survival than chlorambucil-obinutuzumab. (Funded by F. Hoffmann-La Roche and AbbVie; ClinicalTrials.gov number, NCT02242942.).

Bookmark

Cite This Study

Fischer et al. (Tue,) studied this question.

synapsesocial.com/papers/69df6e4258b92af24d7a18ee https://doi.org/https://doi.org/10.1056/nejmoa1815281

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Traditional multiplicity adjustment methods in clinical trials2013 · 158 citations
2Prediction of Creatinine Clearance from Serum Creatinine2008 · 15,388 citations
3A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis1981 · 1,765 citations
4Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients2016 · 19 citations
5The Tumor Lysis Syndrome2011 · 985 citations

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Traditional multiplicity adjustment methods in clinical trials2013 · 158 citations
2Prediction of Creatinine Clearance from Serum Creatinine2008 · 15,388 citations
3A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis1981 · 1,765 citations
4Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients2016 · 19 citations
5The Tumor Lysis Syndrome2011 · 985 citations

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions | Synapse